My ePortfolio Register   

ESMO 2017 /
ARIEL3: Rucaparib as maintenance therapy in recurrent ovarian cancer patients

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 802
Rating:

Prof Jonathan Ledermann - University College London Hospitals, London, UK

Prof Ledermann speaks with ecancer at the ESMO 2017 Congress about the phase III ARIEL3 study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma.

He states that rucaparib has anti-tumour activity in BRCA-mutant or BRCA wild-type/genomic loss of heterozygosity high associated ovarian carcinoma.

He goes on to discuss the results of the study highlighting that rucaparib significantly improved progression-free survival vs placebo in all primary analysis groups of patients with platinum-sensitive, recurrent ovarian carcinoma.

Improvement in progression-free survival was observed in non-nested subgroups of patients with BRCA wild-type ovarian carcinoma. 

Read more about the results here.


ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence